In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. Supply-side sources included CEOs, VPs of Manufacturing, R&D heads, regulatory affairs managers, and commercial directors from stilbene manufacturers, chemical synthesis companies, botanical extract suppliers, and OEMs. Demand-side sources comprised product development managers, procurement leads, and quality assurance heads from dietary supplement manufacturers, cosmetic formulators, pharmaceutical companies, and food & beverage processors. Primary research validated market segmentation, confirmed product pipeline timelines, and gathered insights on raw material sourcing patterns, pricing strategies, formulation trends, and regulatory compliance dynamics.
Primary Respondent Breakdown:
By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)
By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)
Global market valuation was derived through revenue mapping and production volume analysis. The methodology included:
Identification of 50+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America
Product mapping across resveratrol, pterostilbene, genistein, daidzein, and other stilbene types
Source-based segmentation analysis across natural (plant-derived) and synthetic (chemical synthesis) production methods
Application mapping across dietary supplements, cosmetics, pharmaceuticals, and food & beverages
Analysis of reported and modeled annual revenues specific to stilbene product portfolios
Coverage of manufacturers representing 72-78% of global market share in 2024
Extrapolation using bottom-up (production volume × ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations